Exciton Technologies Inc.

Ordering / Info

  Toll Free: 1.855.248.5868
  Fax: 1.780.248.5878
  Email: sales@excitontech.com
Or
Use our
Online Form >>

Search

Home » News » Exciton Lands Distribution Agreement for US Veteran Health Facilities

News

Exciton Lands Distribution Agreement for US Veteran Health Facilities

Tuesday 28 June 2011
Last Updated on Monday 28 November 2011
Edmonton, Alberta – June 29, 2011: Exciton Technologies Inc.today announced the Company has signed a distribution agreement with Marathon Medical, adding them to the existing Federal Supply Schedule (FSS) contract, administered by the Department of Veterans Affairs on behalf of the U.S. General Services Administration (GSA), effective July 1st.
 
“We are excited about partnering with Marathon Medical to reach this important milestone in our commercialization efforts” says Rod Precht, President and Founder, Exciton Technologies Inc. “Since receiving approval to market the exsalt™ SD7 Wound Dressing in the US and Canada, it has been our goal to secure a place on formularies of hospitals. A listing on the FSS offers access to this effective wound care product at the lowest available price."
 
“Adding Exciton to our supply schedule just made sense,” says John St. Leger, President, Marathon Medical.   “What is unique about Exciton’s product is the superior attributes over other leading silver technologies. At Marathon Medical, we combine excellent products with competitive pricing to bring the greatest value to the veteran patient.”
 
The arrangement allows Exciton to expand the availability of its exsalt™ SD7 Wound Dressing throughout the entire federal healthcare system, the largest healthcare provider in the United States with over 1,300 Veterans health facilities, Department of Defense, Military Hospitals, and other government agencies.
 
A recent resurgence in the use of silver dressings has been largely due to an increase in the number of antimicrobial-resistant organisms. With a long history of safety, silver continues to be the most promising antimicrobial treatment in the market. Initial evaluations of the exsalt™ SD7 Wound Dressing within the US over the last year are validating the performance of this next generation product within a rapidly growing market.
 
About exsalt™ SD7 Wound Dressing
The exsalt™ SD7 Wound Dressing is indicated for use on partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, and other acute or chronic wounds.  The exsalt™ SD7 Wound Dressing maintains its broad spectrum antimicrobial activity for up to seven days. 

For Corporate or Investment information:
Rod Precht
President & Founder
Exciton Technologies Inc.
Phone:780-248-5868
E-mail:rprecht@excitontech.com
Website: www.excitontech.com

For Ordering Information:
John St. Leger
President
Marathon Medical.
Toll free: 877-431-4753 or 303-339-4305
E-mail: jfs@marathonmed.com
www.marathonmed.com

BACKGROUND

About Exciton Technologies Inc.
Exciton Technologies Inc. is a privately held Alberta advanced materials research and development company focused on the creation of technologies for preventing and controlling infection. Currently our valuable portfolio of patentable platform technologies is based on the antimicrobial properties of silver. The Company’s technologies offer next-generation and less expensive products, enabling the company to participate in many industries, including the wound care and disinfectant markets.

About Marathon Medical
Marathon Medical is a Service Disabled Veteran Owned Small Business and verified by the Center for Veterans Enterprise, providing the highest quality products and services at competitive prices creating the best value for its customers. They serve the health care industry nationwide with products and services that help hospitals and pharmacies reduce costs, improve productivity and deliver better care to patients.

Forward-looking Statements
This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

Find us on the web:

linked in twitter facebook Youtube
© Exciton Technologies Inc. 2010